Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Nov;145(11):2751-2759.
doi: 10.1007/s00432-019-03021-y. Epub 2019 Sep 30.

Active surveillance of low-risk papillary thyroid carcinoma: a promising strategy requiring additional evidence

Affiliations
Review

Active surveillance of low-risk papillary thyroid carcinoma: a promising strategy requiring additional evidence

Yuyang Ze et al. J Cancer Res Clin Oncol. 2019 Nov.

Abstract

Purpose: Papillary thyroid carcinoma (PTC), the most common malignant tumor of the thyroid, has been criticized as overtreated by some researchers in recent years. Active surveillance (AS) was first proposed at Kuma Hospital in 1993, and popularized in other institutes ever since. We provide a brief review of low-risk PTC active monitoring studies to date, and discuss the advantages of AS and limitations of existing studies.

Results: Most papillary thyroid microcarcinomas do not show significant growth or new lymph node metastasis in a 10-year AS period. Patients who undergo delayed surgery during AS generally have a good prognosis. Tumor progression correlates with age, calcification pattern, and Ki-67 positivity. Serum thyroid stimulating hormone concentration and pregnancy might also influence tumor progression in some studies.

Conclusion: Active surveillance for low-risk PTC has shown its safety and feasibility in certain populations. In the future, it is warranted to determine valuable tumor progression predictors and most suitable PTC patients for AS.

Keywords: Active surveillance; Low-risk; Observation; Papillary carcinoma; Thyroid.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Natl Cancer Inst. 2003 Apr 16;95(8):625-7 - PubMed
    1. Histopathology. 1990 May;16(5):513 - PubMed
    1. Endocrine. 2018 Feb;59(2):275-279 - PubMed
    1. Thyroid. 2011 Aug;21(8):917-20 - PubMed
    1. Thyroid. 2014 May;24(5):840-4 - PubMed

MeSH terms

LinkOut - more resources